Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | A Phase 0 ‘Trigger’ trial of pamiparib in newly diagnosed and recurrent glioblastoma patients

Nader Sanai, MD, Barrow Neurological Institute, Phoenix, AZ, discusses the results of a Phase 0 ‘trigger’ trial of pamiparib, a PARP1/2 inhibitor, in newly diagnosed and recurrent glioblastoma patients. The Phase 0 trial demonstrated pamiparib can effectively penetrate the CNS in both newly diagnosed and recurrent glioblastoma. Additionally, evidence of the molecular effect of pamiparip target inhibition was observed, as well as synergy with radiation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.